Compass Therapeutics (CMPX) Depreciation and Depletion (2020 - 2026)

Compass Therapeutics has disclosed Depreciation and Depletion across 7 years of filings, most recently posting $15000.0 for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $15000.0, down 89.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $175000.0 (down 67.59% YoY), and the FY2025 annual result was $300000.0, down 50.0% from the prior year.
• Depreciation and Depletion came in at $15000.0 for Q1 2026 at Compass Therapeutics, down from $100000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $200000.0 in Q1 2022 to a low of $15000.0 in Q1 2026.
• The 5-year median for Depreciation and Depletion is $200000.0 (2022), against an average of $150937.5.
• Across the five-year window, Depreciation and Depletion surged 100.0% in 2022 and tumbled 89.29% in 2026, its largest moves.
• Compass Therapeutics' Depreciation and Depletion stood at $200000.0 in 2022, then changed by 0.0% to $200000.0 in 2023, then slumped by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then plunged by 85.0% to $15000.0 in 2026.
• The last three Depreciation and Depletion figures came in at $15000.0 (Q1 2026), $100000.0 (Q3 2025), and $60000.0 (Q2 2025), per Business Quant data.